December 22
QLT Announces Departure of Chief Business Officer
PDF version
December 14
QLT Announces Partial Result in Eligard� Patent Litigation
December 13
QLT Announces TSX Approval to Increase its Share Repurchase Program to $100 Million
December 7
QLT Announces Repositioning and Streamlining for Future Growth
December 5
QLT to Host Conference Call to Discuss Strategic Update
October 27
QLT Announces Q3 Results for 2005
October 18
QLT Announces Visudyne® Sales for Third Quarter of 2005
September 25
President and CEO Paul Hastings steps down
September 20
QLT Announces Two Year Results of Visudyne� in Occult (VIO) Trial
August 9
QLT Appoints Cameron Nelson as Vice President, Finance and Chief Financial
Officer
July 28
QLT Announces Q2 Results for 2005 and Revises Guidance
July 13
QLT Announces Visudyne� Sales for Second Quarter of 2005
July 7
ACZONE™ Gel is Approved for the Treatment of Acne by the FDA
July 5
QLT Acquires Full Rights to ACZONE™, By Mutual Agreement with Astellas
May 2
QLT Announces TSX Approval of US $50 Million Share Repurchase Program
April 28
QLT Announces Q1 Results for 2005 and Reiterates Guidance
April 21
QLT Announces Visudyne® Sales for First Quarter of 2005
April 11
QLT Announces Senior Management Changes
February 28
Sosei Files Japan Marketing Authorization Application for Prostate Cancer Drug SOT-375
February 23
QLT Announces 2004 Results and Outlook for 2005
February 18
Aczone Data Demonstrates Reduction in Number and Severity of Acne Lesions
February 17
Commercial Availability of QLT’s Eligard® 6-Month Formulation Brings New Treatment Option for Advanced Prostate Cancer
January 26
QLT Announces Favorable Court Decision in Massachusetts Eye and Ear Infirmary (MEEI) Patent Litigation
QLT Announces Eligard� Sales For 2004
January 20
QLT Announces Visudyne� Sales for Fourth Quarter and Fiscal Year 2004
